<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578110</url>
  </required_header>
  <id_info>
    <org_study_id>OPTH_DEV_GLAU_02</org_study_id>
    <secondary_id>1R43EY015015-01</secondary_id>
    <secondary_id>1R43EY015015-02</secondary_id>
    <secondary_id>1R43EY015015-03</secondary_id>
    <nct_id>NCT00578110</nct_id>
  </id_info>
  <brief_title>Instrument for Glaucoma Early Detection and Monitoring</brief_title>
  <acronym>IGDM</acronym>
  <official_title>SBIR II Instrument for Glaucoma Early Detection and Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synabridge Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Synabridge Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To introduce a rapid and objective electrophysiological technique that can assess visual
      function in the magnocellular pathway, which is thought to be affected in early-stage
      glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical study will evaluate a novel instrument designed to record visual evoked
      potentials elicited by stimuli determined in prior research (Greenstein et al., 1998; Badr et
      al., 2003) to drive select visual pathways that exhibit glaucomatous damage in an efficient
      and automated manner. The results obtained with this novel device will be compared with
      results obtained using an existing commercial device. Statistical results, sensitivity and
      specificity, will be generated for the assessment of the accuracy of the test to discriminate
      glaucoma patients from controls. Repeatability of the test will also be analyzed based on the
      test-retest results.

      Visual evoked potential (VEP) is a measure of neural function in the eye and brain. Three
      skin electrodes are placed on the surface of the scalp to record the electrical activity from
      the brain while the subject is observing a flickering stimulus with isolated-check/dot
      pattern. The whole procedure is non-invasive and the risks are negligible.

      Isolated-Check/dot Stimuli of about 10 Hz with luminance contrast of 10%, 15%, -10%, and -15%
      will be used to test each eye. Eight samples for each stimulus will be recorded. Each
      experimental run takes 2 seconds. The T-circ statistical method is performed to process the
      data, and the VEP signal to noise ratio (SNR) is calculated in order to obtain an optimized
      condition (stimulus and threshold) to separate glaucoma patients and normal group.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sensitivity and specificity</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>repeatability</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glaucoma Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glaucoma suspects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glaucoma Diagnosis, Name: Neucodia</intervention_name>
    <description>Sensitivity and Specificity</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>NEUCODIA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 40 - 75 years old

          -  Visual acuity: 20/30 or better

        Exclusion Criteria:

          -  Eye disease other than glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Hu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Synabridge Corp.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Tsai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Max Forbes, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vivienne Greenstein, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugenue Hartmann, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Netland, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leo Pau Semes, O.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vance M Zemon, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Yeshiva University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarwat Salim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Swanson, OD</last_name>
    <role>Study Director</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George Hu, Ph.D.</last_name>
    <phone>(908) 725-5213</phone>
    <email>georgehu@synabridge.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vance Zemon, Ph.D.</last_name>
    <phone>(845) 627-0320</phone>
    <email>vepman@aol.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>School of Optometry, University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naser T Naser</last_name>
      <phone>205-222-4543</phone>
      <email>dcnaser@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eugenie Hartmann, Ph.D.</last_name>
      <phone>205-975-3143</phone>
      <email>EEHartmann@uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eugenie Hartmann, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Eye Center, Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Leone</last_name>
      <phone>203-785-6150</phone>
      <email>ann.leone@yale.edu</email>
    </contact>
    <investigator>
      <last_name>James C Tsai, M.D. MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synabridge Corp.</name>
      <address>
        <city>Raritan</city>
        <state>New Jersey</state>
        <zip>08869</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Hu, Ph.D.</last_name>
      <phone>908-725-5213</phone>
      <email>georgehu@synabridge.com</email>
    </contact>
    <investigator>
      <last_name>George Hu, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edward S. Harkness Eye Institute, Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hamilton Eye Institute, The University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103-3452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarwat Salim, MD</last_name>
      <phone>901-351-0777</phone>
      <email>sarwat_salim@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>George Hu, Ph.D.</last_name>
      <phone>908-803-7040</phone>
      <email>gehu@verizon.net</email>
    </contact_backup>
    <investigator>
      <last_name>Peter A Netland, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarwat Salim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.springerlink.com/content/c61kn0763352xqh8/</url>
    <description>Journal Article: Novel electrophysiological instrument for rapid and objective assessment of magnocellular deficits associated with glaucoma</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2007</study_first_posted>
  <last_update_submitted>April 1, 2010</last_update_submitted>
  <last_update_submitted_qc>April 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>George Hu, President</name_title>
    <organization>Synabridge Corp.</organization>
  </responsible_party>
  <keyword>glaucoma VEP detection device diagnosis vision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

